Saxol on  Capital Cell

Saxol is leading a breakthrough in oncology with the development of the first drug designed to prevent peripheral neuropathy, a condition that affects 70% of chemotherapy patients.

Estimated return of 2000% with potential exit in 2030

Industry - HealtTech 

Raising- 1.500.000 EUR

Valuation (pre-money) - 7.100.000  EUR

Company and product stage - In vitro/proof of concept

What problem Saxol is solving?

Fighting cancer also means helping patients cope with their treatments. Saxol is leading a breakthrough in oncology with the development of the first drug designed to prevent peripheral neuropathy, a condition that affects 70% of chemotherapy patients.

Peripheral neuropathy causes severe, persistent pain, sometimes forcing doctors to lower doses or even halt treatment, reducing its effectiveness. Saxol’s lead compound, Carba1, is believed to protect up to 100% of the nerves and nerve fibers affected by chemotherapy, significantly improving patients’ quality of life and long-term health.

Clinical trials will begin in 2028, with an out-licensing sale of the program to a big pharma planned for 2030 to finalize development, obtain marketing authorizations (MAs) and commercialize the treatment.

Flakon on Tudigo

Let's democratize access to fine wines through wine and spirits gift sets

Estimated return of up to 580%

Industry -  FoodTech 

Company and product stage - Since its inception, with a CAGR of +130% and cumulative revenue of +€3.9M, it has notably sold more than 400,000 bottles to more than 40,000 unique customers.

What problem Flakon is solving?

Flakon offers a concrete and innovative solution to democratize oenology and access to great wines:

• A high financial cost : the entry price of a rare wine is on average €100
• A lack of expertise : 54% of consumers consider a lack of knowledge as a barrier
• An exclusive : rare wines represent only 1% of the total volume of wine produced

Flakon has developed a 100% e-commerce business model with a unique concept:

• Tasting boxes containing 3 to 12 bottles of exceptional wines and spirits
• Innovative format : 1 bottle is equivalent to 2 tasting glasses
• Immersive experience guided by videos and explanatory booklets
• Patented bottles guaranteeing optimal conservation for up to 3 years

What is Flakon market potential?

Positioned in a market representing +€3.4 billion in France, growing at a rate of +6% per year. Already generating +15% of its turnover internationally, the global market opportunity amounts to €74 billion.

Level E Research on  Crowdcube

Level E is an Edinburgh-based FinTech that builds AI agents to address all components of asset management. Its go-to-market AI Compliance Agent is powered by a proprietary autonomous platform, delivering cost reductions while increasing efficiency, output, and performance.

Company and product stage - Intelligent systems, human-like responses, validated by top firms, like Aberdeen and M&G

Industry -  AI / Compliance

Raising 400,000 GDP 

Valuation (pre-money) - 23,445,990 GDP

What problem Level E Research is solving?

Problem - Asset managers have legacy infrastructure, spiralling costs/inefficiencies, and increased regulation. This is prevalent in Compliance. To improve profitability/output they must embrace technology.

Solution - Our AI-driven solution, AICA, enhances compliance by automating data analysis, reducing costs and increasing productivity. It aims to be one of the first AI agents to optimise asset management.

What is Level E Research market potential?

We look to target asset managers with $ 10 B+ AUM, focusing on 500 global firms, including 121 EU and 40 UK firms.

Phlo Systems  on  Crowdcube

Phlo Systems delivers robust, AI-powered, SaaS-based solutions that increase efficiency, simplify international trade and supply chain management for SME customers. Solutions also deliver superior and accessible end-to-end ERP and risk management functionality for commodity importers and exporters, traders and processors

Company and product stage -

Industry -   AI / Transportations 

Raising - 450,000 GDP 

What problem Phlo Systems is solving?

Problem - Changing regulations and increasing compliance challenges impact UK importers and exporters, business growth and complexity impact all commodities businesses and increased fraud and risk impact the ability to secure trade finance

Solution - Our SaaS solutions increase efficiency, reduce compliance errors, standardize datasets for better decisions, and unlock trade finance

What is Phlo Systems  market potential?

We serve three global markets: customs & logistics ($8.58bn), global supply chain management ($20bn), and trade financial market ($4.3tn).

smedo  on SeedBlink

smedo offers world‘s most advanced contactless biometrics.

Industry - MedTech 

Raising - 400.000 EUR

Company and product stage - Active onboarding of clients across academia, enterprise healthcare, and government organizations.

What problem smedo is solving?

Current methods for recording vital signs in hospitals are labor-intensive, time-consuming, inaccurate and cost-intensive. Manual documentation by nursing staff is inefficient and does not provide continuous data. This leads to gaps in patient monitoring and delayed data availability for decision-making. The increasing workload of nursing staff and cost pressure in healthcare facilities intensify this problem.

smedo offers a contactless technology for monitoring vital functions using high-frequency radar that measures micro-vibrations of the skin. The system enables accurate and continuous (24/7) recording of heart rate, respiratory rate and heart muscle sounds. The data is automatically documented and integrated into hospital information systems. The technology is validated and has an accuracy of 98% compared to ECG data from the hospital. smedo has already developed two prototypes and plans to launch in the US in 2026 and in Europe in 2027. The company has successfully completed several rounds of financing, including public funding.

What is smedo market potential?

The addressable market (TAM) for medical devices in hospitals and care facilities is estimated at USD 80 billion. The potential Serviceable Achievable Market (SAM) for vital signs monitoring in this area is USD 32 billion. smedo targets a Serviceable Obtainable Market (SOM) of 250 million US dollars per year in hospitals and care facilities with a market share of 5%. The growing demand for continuous health monitoring due to an ageing population and the increase in chronic diseases offers significant growth potential.

Televitas on Spreds 

Your universal e-health ecosystem

Industry - Medtech 

Raising - 450,000 EUR

Valuation (pre-money) - 3,000,000 EUR

What problem Televitas is solving?

Televitas bridges these gaps through an open, modular platform that enables seamless collaboration between all stakeholders—healthcare providers, patients, employers, insurers, and social networks. It supports prevention, well-being, and recovery through fully integrated tools and services.

Key Challenges in Healthcare Today:

• Outdated care models: Episodic care dominates, lacking long-term follow-up.
• Poor interoperability: Systems and devices often don’t talk to each other.
• High administrative burden: Providers spend too much time on paperwork.
• Underused technology: Sensors and wearables aren't widely adopted in practice.

Televitas Responds With

• Predictive data analysis to detect health issues early.
• Interoperable infrastructure for seamless data exchange across systems.
• Workflow automation that reduces administrative tasks.
• Inclusive communication tools like video calling, messaging, and TV interfaces for all users—including non-digital natives.

REO  on  Companisto

Award-winning ConversationalAI application for the future of job applications, with international growth and renowned partners such as NHS and SAP.

Estimated return of 547%%

Industry - Sustainable packaging 

Raising - 500,000 EUR

Valuation (pre-money) - 3,500,000  EUR 

Company and product stage - Reo has completed a 12-month proof of concept with Edeka and its own brand, developed a tracking dashboard, and integrated with major deposit machine manufacturers.

What problem REO  is solving?

Problem:

The personal care industry faces increasing pressure from regulators and consumers to move away from single-use packaging. EU laws such as the Packaging and Packaging Waste Regulation (PPWR), along with rising CO₂ taxes and sustainability mandates, require packaging to be reusable and recyclable. However, the industry lacks a scalable, standardized, and open reuse system—especially for complex personal care packaging. Most existing reuse solutions are closed, analog systems that don’t allow interoperability or meaningful data collection.

Solution:

Reo has developed a digital, open, and agnostic reuse platform for personal care packaging that transforms any existing packaging into a reusable and trackable unit through a unique identifier (2D Data Matrix code). It orchestrates the reuse cycle by integrating with existing deposit return infrastructures (e.g., Tomra and Sielaff machines in supermarkets), coordinating refurbishing partners, and enabling brands to recollect and refill packaging. The platform also provides CSR and customer behavior data through its software dashboard, allowing brands to track sustainability metrics, reduce costs, and comply with environmental regulations without changing their packaging design or supply chains.

What is REO  market potential?

The total addressable market (TAM) for reusable personal care packaging in the EU is €10.87 billion by 2030. The serviceable available market (SAM) is estimated at €1.03 billion, with a serviceable obtainable market (SOM) target of €31 million in revenue by 2030.

Artknit Studios on CrowdFundMe

B Corp redefining luxury with an M2C model, connecting Italian excellence to global consumers through a short, digital and sustainable supply chain

Industry - Fashion 

Raising - 300.000 EUR

Valuation (pre-money) - 7.299.990  EUR 

Company and product stage - Presence on the foreign market already tested in Europe and the USA

Project and business model description of Althink

Founded in Biella in 2019, Artknit Studios redefines the concept of accessible luxury thanks to a Manufacturer-to-Consumer (M2C) model that eliminates intermediaries and optimizes the entire production chain. This approach allows to offer high-quality Made in Italy knitwear at a competitive price , while maintaining control and transparency over the entire supply chain.

The company uses a proprietary digital platform that directly connects the best Italian manufacturers to global consumers, ensuring traceability, operational efficiency and waste reduction.

The vertical integration of the business model allows Artknit Studios to improve margins and increase scalability, thanks to a data-driven approach that optimizes production, logistics and inventory management.

Revenues are generated through direct sales , both online and offline, without going through the wholesale model. This allows the company to maintain a direct relationship with its customers, increase customer lifetime value and improve economic efficiency.

Don’t miss out on amazing investment opportunities follow us on LinkedIn or Facebook and learn more about crowdfunding on Crowdinform.com 

We wish you a good day and successful investing!

CrowdInform